Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Province Implements Pilot Quality System To Strengthen Drug Safety

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - In the latest effort to strengthen drug safety measures in China, Guangdong province has taken a page out of the international quality systems playbook, launching a pilot system July 20 that assigns responsibility for drug manufacturing quality to a designated company official

You may also be interested in...



SFDA Issues Revised GMP Draft Guideline Following Industry Comments; Expects Compliance To Come In Stages

SHANGHAI - Following industry comments, China's State FDA released another draft GMP guideline for which it seeks additional public comments. The revised draft offers clarity on a few key points but still leaves huge gaps that will need to be filled slowly over time

SFDA Issues Revised GMP Draft Guideline Following Industry Comments; Expects Compliance To Come In Stages

SHANGHAI - Following industry comments, China's State FDA released another draft GMP guideline for which it seeks additional public comments. The revised draft offers clarity on a few key points but still leaves huge gaps that will need to be filled slowly over time

China's FDA Issues Revised GMP Draft Guideline Following Industry Comments; Expects Compliance To Come In Stages

"It will be interesting to see how much of a grace period is given for manufacturers to meet standards, or whether certain manufacturers will be 'grandfathered' under old rules," industry consultant says.

Related Content

UsernamePublicRestriction

Register

SC066391

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel